Develops biopharmaceuticals for oncology and autoimmune diseases, focusing on targeted therapies and immunomodulation.
MAIA Biotechnology, Inc. is a clinical-stage biotechnology firm focused on pioneering therapies aimed at combatting cancer. At the forefront of its innovative pipeline is THIO, a telomere-targeting agent currently undergoing Phase II clinical trials. This investigational drug is designed to assess its efficacy in treating patients with non-small cell lung cancer, marking a significant advancement in cancer therapy research. In addition to THIO, MAIA Biotechnology is actively developing next-generation telomere-targeting agents to expand its therapeutic portfolio.
Headquartered in Chicago, Illinois, MAIA Biotechnology, Inc. oprerates within a dynamic landscape of biomedical innovation. The company's strategic focus on oncology underscores its commitment to addressing unmet medical needs and improving outcomes for cancer patients globally. With a dedicated team of researchers and clinicians, MAIA Biotechnology continues to push the boundaries of cancer treatment through cutting-edge science and clinical expertise.
Founded on a mission to transform cancer care, MAIA Biotechnology, Inc. leverages rigorous scientific research and development to drive advancements in the biopharmaceutical sector. Through its relentless pursuit of novel therapeutic solutions, the company aims to deliver meaningful impact in the fight against cancer, offering hope and new possibilities for patients and their families.